Your session is about to expire
← Back to Search
Device Validation Using Blood Samples for Thrombotic Thrombocytopenic Purpura
N/A
Recruiting
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial is for a new device that needs to be validated with known samples. 3 ml of blood is needed from people diagnosed with hTTP. You will be compensated for your time and resources.
Who is the study for?
This trial is for individuals with hereditary thrombotic thrombocytopenic purpura (hTTP) who have an ADAMTS13 activity level below 1%. Participants will provide a small blood sample and receive $500 for their time.
What is being tested?
The study involves a single blood draw to help validate a new diagnostic device. The company behind this has other devices on the market, and needs real patient samples to ensure the new instrument works correctly.
What are the potential side effects?
Since the intervention only includes drawing blood, side effects are minimal but may include slight pain or bruising at the needle site, dizziness, or fainting.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
1Treatment groups
Placebo Group
Group I: ParticipantsPlacebo Group1 Intervention
Anyone with Hereditary TTP
Find a Location
Who is running the clinical trial?
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a genetic condition known as TTP.My ADAMTS13 activity level is below 1%.
Research Study Groups:
This trial has the following groups:- Group 1: Participants
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.